PATENT CLAIM ANALYSIS

Application Number: 15899499
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "023000"]

Abstract:
The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

Claim (Index 1):
A method of treating, preventing, protecting against, reducing the risk of, delaying the occurrence of and/or delaying the progression of chronic kidney disease in a patient, said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.

Metadata:
- Claim Count in Document: 89.0
- Percentile: 88.0
- Lexical Diversity: 1.17647
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14918713', '14918727', '15616974', '13833097', '15523512']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7525369914645279
- 35 USC 102 Novelty (BERT): 0.5550080534982164
- Combined Prediction Score: 0.7327840976678968
- Mean Citation Score: 382.242474
- Max Citation Score: 438.56375
- Similarity Product: 341.13023951694373

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test